The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016
Prostate Cancer and Prostatic Diseases · 2025
DOI: 10.1038/s41391-024-00822-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostate Cancer and Prostatic Diseases, 2025. Verfasst von Cooper Desmond und 9 weiteren Autor:innen. Beteiligte Einrichtung: Williams College, Williamstown, MA, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Overtreatment, Adenocarcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although active surveillance is the preferred management for low-risk prostate cancer (PCa), some men remain at risk of overtreatment with definitive local therapy. We hypothesized that baseline characteristics may be associated with overtreatment and represent a potential source of health disparities. We therefore examined the associations of patient and disease characteristics with the surgical overtreatment of low-risk PCa. METHODS: We identified men aged 45-75 years with cT1 cN0 cM0 prostate adenocarcinoma with biopsy Gleason score 6 and PSA < 10 ng/ml from 2010-2016 in the National Cancer Database (NCDB) and who underwent radical prostatectomy (RP). We evaluated the associations of baseline characteristics with clinically insignificant PCa (iPCa) at RP (i.e., "overtreatment"), defined as organ-confined (i.e., pT2) Gleason 3 + 3 disease, using multivariable logistic regression. RESULTS: We identified 36,088 men with low-risk PCa who underwent RP. The unadjusted rate of iPCa decreased during the study period, from 54.7% in 2010 to 40.0% in 2016. In multivariable analyses adjusting for baseline characteristics, older age (OR 0.98, 95% CI 0.97-0.98), later year of diagnosis (OR 0.62, 95% CI 0.57-0.67 for 2016 vs. 2010), Black race (OR 0.85, 95% CI 0.79-0.91), treatment at an academic/research program (OR 0.82, 95% CI 0.73-0.91), higher PSA (OR 0.91, 95% CI 0.90-0.92), and higher number of positive biopsy cores (OR 0.87, 95% CI 0.86-0.88) were independently associated with a lower risk of overtreatment (iPCa) at RP. Conversely, a greater number of biopsy cores sampled (OR 1.01, 95% CI 1.01-1.02) was independently associated with an increased risk of overtreatment (iPCa) at RP. CONCLUSIONS: We observed an ~27% reduction in rates of overtreatment of men with low-risk PCa over the study period. Several patient, disease, and structural characteristics are associated with detection of iPCa at RP and can inform the management of men with low-risk PCa to reduce potential overtreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Williams College, Williamstown, MA, USA.
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Division of Urology, University of Colorado Anschutz Medical Center, Aurora, CO, USA.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. bgershma@bidmc.harvard.edu.
Zitieren
APA
Desmond, C., Kaul, S., Fleishman, A., Korets, R., Chang, P., Wagner, A., Kim, S. P., Aghdam, N., Olumi, A. F., & Gershman, B. (2025). The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00822-2
Vancouver
Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, et al. The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. Prostate Cancer and Prostatic Diseases. 2025. doi:10.1038/s41391-024-00822-2
BibTeX
@article{Desmond2025,
author = {Desmond, Cooper and Kaul, Sumedh and Fleishman, Aaron and Korets, Ruslan and Chang, Peter and Wagner, Andrew and Kim, Simon P and Aghdam, Nima and Olumi, Aria F and Gershman, Boris},
title = {The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2025},
doi = {10.1038/s41391-024-00822-2}
}
EUVIMED